Paul  Rivard net worth and biography

Paul Rivard Biography and Net Worth

Paul Rivard, Esq., was appointed Executive Vice President of Operations and General Counsel of MYMD Florida effective as of September 21, 2020. Prior to joining MYMD Florida, Mr. Rivard was a principal shareholder of Banner Witcoff, a national law firm specializing in intellectual property law, from 2003-2020, and in that capacity also served as Chair of the firm’s Prosecution Policies and Procedures Committee, developing and refining internal procedures, workflow, and docketing practices to improve efficiencies and mitigate risk. Before becoming a principal shareholder, Mr. Rivard was an associate at Banner Witcoff from 1998-2002. In addition, prior to his time at Banner Witcoff, Mr. Rivard served as a patent examiner for the United States Patent and Trademark Office from 1992-1998. Mr. Rivard brings more than 20 years of experience as intellectual property counsel for clients ranging from startups to Fortune 100 companies in the life sciences, chemical and consumer product industries, including primary outside intellectual property counsel for MYMD Florida from 2014-2020. Mr. Rivard has worked closely with strategic decision makers and in-house counsel of his numerous clients, seeking to align intellectual property procurement, enforcement and licensing strategies with business objectives. Mr. Rivard received his Juris Doctor from Catholic University of America’s Columbus School of Law, graduating cum laude in 1998, and his B.S. in Chemical Engineering from Clarkson University in 1992.

What is Paul Rivard's net worth?

The estimated net worth of Paul Rivard is at least $17,732.89 as of August 24th, 2023. Mr. Rivard owns 13,333 shares of MyMD Pharmaceuticals stock worth more than $17,733 as of November 2nd. This net worth approximation does not reflect any other assets that Mr. Rivard may own. Learn More about Paul Rivard's net worth.

How do I contact Paul Rivard?

The corporate mailing address for Mr. Rivard and other MyMD Pharmaceuticals executives is 855 N. WOLFE STREET, BALTIMORE MD, 21205. MyMD Pharmaceuticals can also be reached via phone at 856-848-8698 and via email at [email protected]. Learn More on Paul Rivard's contact information.

Has Paul Rivard been buying or selling shares of MyMD Pharmaceuticals?

Paul Rivard has not been actively trading shares of MyMD Pharmaceuticals within the last three months. Most recently, on Thursday, August 24th, Paul Rivard bought 5,000 shares of MyMD Pharmaceuticals stock. The stock was acquired at an average cost of $33.30 per share, with a total value of $166,500.00. Following the completion of the transaction, the insider now directly owns 13,333 shares of the company's stock, valued at $443,988.90. Learn More on Paul Rivard's trading history.

Who are MyMD Pharmaceuticals' active insiders?

MyMD Pharmaceuticals' insider roster includes Paul Rivard (EVP), and Joshua Silverman (Director). Learn More on MyMD Pharmaceuticals' active insiders.

Paul Rivard Insider Trading History at MyMD Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/24/2023Buy5,000$33.30$166,500.0013,333View SEC Filing Icon  
12/8/2022Buy333$45.90$15,284.707,500View SEC Filing Icon  
11/23/2021Buy500$180.90$90,450.00View SEC Filing Icon  
See Full Table

Paul Rivard Buying and Selling Activity at MyMD Pharmaceuticals

This chart shows Paul Rivard's buying and selling at MyMD Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

MyMD Pharmaceuticals Company Overview

MyMD Pharmaceuticals logo
MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the aging and age-related and autoimmune diseases, and chronic pain, anxiety, and sleep disorders. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system and its pro-inflammatory cytokines to prevent and treat autoimmune diseases and age-related illnesses, and a Phase 2 clinical trial for sarcopenia, multiple sclerosis, diabetes, inflammatory bowel diseases, and rheumatoid arthritis; inflammation related depression and anxiety; and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic analog of cannabidiol for treating epilepsy, pain, and anxiety/depression. The company was founded in 2014 and is headquartered in Baltimore, Maryland.
Read More

Today's Range

Now: $1.33
Low: $1.31
High: $1.43

50 Day Range

MA: $1.58
Low: $1.19
High: $1.90

2 Week Range

Now: $1.33
Low: $1.75
High: $63.90

Volume

31,860 shs

Average Volume

134,123 shs

Market Capitalization

$3.15 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.15